Does Amerigroup Cover Victoza?

What Is Victoza and Why Does the Diagnosis Code Matter So Much?

Victoza is the brand name for liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily. The FDA approved it in January 2010 for glycemic control in adults with type 2 diabetes, and in August 2017 extended its label to include reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The FDA prescribing information is indexed at accessdata.fda.gov.

The diagnosis code on the prescription determines almost everything about Amerigroup coverage. A claim filed under ICD-10 E11 (type 2 diabetes mellitus) travels a very different formulary path than one filed under E66 (obesity). Medicaid programs in most states explicitly exclude weight-loss drugs from coverage unless a separate statutory exception applies, so a prescriber who lists only obesity as the indication may trigger an automatic denial even when the patient also has diabetes.

How Liraglutide Works Clinically

Liraglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. In the LEADER trial (N=9,340 patients with type 2 diabetes and high cardiovascular risk), liraglutide 1.8 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 13% versus placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority and P=0.01 for superiority). Read the LEADER trial results in the New England Journal of Medicine.

That cardiovascular outcome data is clinically significant for coverage purposes. A patient with documented atherosclerotic cardiovascular disease alongside type 2 diabetes has an on-label reason for Victoza that goes beyond glucose control, which may strengthen a prior authorization request.

Victoza Versus Saxenda: Why the Distinction Matters for Insurance

Novo Nordisk markets a higher-dose version of liraglutide, Saxenda (3.0 mg), specifically for chronic weight management. Amerigroup and most Medicaid programs treat Victoza and Saxenda as separate drugs on separate formulary tiers. Saxenda is almost universally excluded from Medicaid formularies because federal Medicaid law (42 U.S.C. § 1396r-8) prohibits reimbursement for drugs used for weight loss, cosmetic purposes, or symptomatic relief. Victoza at 1.2 mg or 1.8 mg prescribed for diabetes does not fall under that exclusion.

How Amerigroup Structures Its Formularies

Amerigroup, now operating as Anthem's Medicaid and Medicare Advantage subsidiary in multiple states, does not publish a single national formulary. Each state contract produces its own preferred drug list (PDL), and those lists are updated quarterly. As of early 2025, Amerigroup operates Medicaid managed care programs in Georgia, Indiana, Kansas, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas, Virginia, Washington, and Wisconsin, among others.

Medicaid Formulary Placement

In most Amerigroup Medicaid plans, Victoza appears on a non-preferred tier or requires prior authorization rather than sitting on a preferred tier with no restrictions. The practical consequence is a two-step process: the pharmacy submits a claim, the claim rejects for prior authorization, and the prescriber must then submit clinical documentation before the drug is dispensed.

A 2022 analysis published in JAMA Internal Medicine examining GLP-1 formulary access across 50 state Medicaid programs found that only 24 states covered at least one GLP-1 agonist for type 2 diabetes on preferred formulary tiers without step therapy. Access that analysis via PubMed.

Medicare Advantage Formulary Placement

Amerigroup Medicare Advantage (including dual-eligible special needs plans) must follow CMS Part D formulary rules. CMS categorizes liraglutide as a covered Part D drug when used for type 2 diabetes. Under Part D, plans must cover at least two drugs in each therapeutic category, and GLP-1 agonists constitute a recognized category. Amerigroup Medicare Advantage plans typically place Victoza on Tier 3 or Tier 4, meaning cost-sharing is higher unless a lower-tier exception is granted.

The CMS Medicare Prescription Drug Benefit manual (Chapter 6) governs formulary exceptions and is the document your prescriber should reference when requesting a tier exception. CMS guidance is available at cms.gov.

Prior Authorization Criteria Amerigroup Typically Applies to Victoza

Prior authorization for Victoza through Amerigroup usually requires documentation of all of the following:

• A confirmed diagnosis of type 2 diabetes mellitus with an HbA1c value reported within the past 12 months
• Documented inadequate response or intolerance to metformin (usually 90 days at a therapeutic dose of at least 1,000 mg twice daily, unless contraindicated)
• Prescriber attestation that the drug is being used for glycemic control, not weight loss
• Current list of all diabetes medications with dates of initiation

Some state plans add a step-therapy requirement through a sulfonylurea or a DPP-4 inhibitor before approving a GLP-1 agonist. The American Diabetes Association 2024 Standards of Care position GLP-1 receptor agonists as preferred agents in patients with established cardiovascular disease, chronic kidney disease, or heart failure, which may support bypassing step therapy in those populations. Review the 2024 ADA Standards of Care at diabetesjournals.org.

Submitting a Strong Prior Authorization Request

A complete PA submission for Victoza through Amerigroup should include the following in a single fax bundle:

1. Completed Amerigroup prior authorization form (drug-specific, available through Availity or the Amerigroup provider portal)
2. Office notes documenting the diabetes diagnosis, current HbA1c, and cardiovascular comorbidities
3. Pharmacy records or prescriber attestation showing prior metformin trial and any other required step-therapy drugs
4. A prescriber letter citing the ADA 2024 Standards of Care if the patient has cardiovascular disease or chronic kidney disease, since those guidelines explicitly support GLP-1 use in those contexts

Processing times vary by state but typically run 3 to 5 business days for standard requests and 24 to 72 hours for urgent requests.

What Happens If Prior Authorization Is Denied

A denial letter must include the specific clinical reason and the appeal deadline. Under federal Medicaid managed care rules (42 CFR § 438.408), Amerigroup must allow at least 90 days for a standard appeal. Expedited appeals must be resolved within 72 hours when the standard timeline would seriously jeopardize the member's health.

The appeal should directly rebut every reason listed in the denial. If the denial cites inadequate step therapy, submit pharmacy records showing the prior drug was tried and failed. If the denial cites missing HbA1c data, attach the lab report.

After an internal appeal fails, members may request an external independent medical review. In most states, external review decisions favorable to the member are binding on the plan.

State-by-State Variability: Why Your ZIP Code Determines Coverage

Because Amerigroup holds separate contracts in each state, the formulary and PA criteria differ materially by location.

Texas

Amerigroup Texas (STAR and STAR+PLUS programs) follows the Texas Medicaid Preferred Drug List maintained by the Texas Health and Human Services Commission. Victoza has historically required PA, with metformin step therapy required unless contraindicated. Texas Medicaid does not cover drugs for weight loss, so the diagnosis must clearly reflect diabetes management.

Georgia

Amerigroup Georgia (Georgia Families program) participates in the state's Preferred Drug List. GLP-1 agonists in Georgia Medicaid have required PA, and the state PDL committee reviews GLP-1 placements annually.

New Jersey

Amerigroup New Jersey (NJ FamilyCare) follows the New Jersey Medicaid PDL. New Jersey has broader prior authorization pathways for GLP-1 agonists in patients with type 2 diabetes who also have documented cardiovascular disease, which aligns with the LEADER trial data supporting Victoza in high-risk populations. LEADER trial data is available at nejm.org.

Tennessee

Amerigroup Tennessee (TennCare) applies its own formulary managed through TennCare Select. Victoza has required PA under TennCare, and step-therapy through metformin and a sulfonylurea has been required in some periods. Patients should request the current TennCare PDL directly from their provider.

The table below summarizes how state plan structure typically affects GLP-1 prior authorization stringency. This is an original HealthRX framework based on publicly available state Medicaid PDL documents and CMS encounter data reviewed in January 2025.

| State | Amerigroup Program | GLP-1 Tier Placement | Step Therapy Required | CVD Exception Pathway | |---|---|---|---|---| | Texas | STAR / STAR+PLUS | Non-preferred, PA required | Metformin first | Limited | | Georgia | Georgia Families | PA required | Metformin first | Case-by-case | | New Jersey | NJ FamilyCare | PA required | Metformin first | Yes, with ASCVD documentation | | Tennessee | TennCare Select | PA required | Metformin + sulfonylurea | Case-by-case | | Nevada | Nevada Medicaid MCO | PA required | Metformin first | Limited | | Indiana | Hoosier Care Connect | PA required | Metformin first | Yes, with documentation |

Alternatives Amerigroup May Cover Instead of Victoza

If Victoza is denied or sits on a high-cost tier, several alternatives may have more favorable formulary placement.

Metformin

Metformin immediate-release and extended-release are generic, inexpensive, and appear on virtually every Medicaid preferred drug list with no prior authorization. The ADA 2024 Standards of Care continue to recommend metformin as a first-line agent for type 2 diabetes in patients without cardiovascular disease, chronic kidney disease, or heart failure when cost is a concern. For a patient who truly cannot tolerate metformin due to gastrointestinal side effects or has an eGFR <30 mL/min/1.73m2, a prescriber letter documenting this contraindication is essential to bypassing step therapy.

Other GLP-1 Agonists

Trulicity (dulaglutide) and Ozempic (semaglutide 0.5 mg or 1.0 mg for diabetes) are GLP-1 agonists that may carry preferred or lower-restriction formulary status in some Amerigroup state plans. In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg or 1.0 mg reduced the composite cardiovascular endpoint by 26% versus placebo (hazard ratio 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority). SUSTAIN-6 results are published at nejm.org. If semaglutide carries a preferred tier status on the applicable Amerigroup PDL, a prescriber may achieve similar clinical outcomes with lower out-of-pocket cost for the patient.

SGLT-2 Inhibitors

For patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease, SGLT-2 inhibitors such as empagliflozin (Jardiance) or dapagliflozin (Farxiga) may be covered on more favorable tiers and provide overlapping cardiovascular and renal benefits. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in patients with type 2 diabetes and established CVD. EMPA-REG OUTCOME data is available at nejm.org. Clinicians should discuss with the patient which agent fits the full clinical picture, not just the formulary.

Patient Assistance and Cost Reduction Options

If Amerigroup denies coverage and appeals are exhausted, several programs may reduce the cost of Victoza.

Novo Nordisk Patient Assistance Program

Novo Nordisk's Cornerstones4Care program offers Victoza at no cost or reduced cost to qualifying patients who meet income requirements. As a general guide, patients with household incomes at or below 400% of the federal poverty level and without adequate insurance coverage may qualify. Applications are submitted directly to Novo Nordisk or through a prescriber's office. Contact information and income thresholds are updated annually at novonordisk-us.com/patients.

NeedyMeds and RxAssist Databases

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain current databases of manufacturer patient assistance programs, state pharmaceutical assistance programs, and disease-specific foundations that may cover GLP-1 costs. These are free to search and updated frequently.

340B Drug Pricing Program

Patients receiving care at a federally qualified health center (FQHC), rural health clinic, or other 340B-covered entity may access Victoza at significantly reduced prices through the 340B program. The Health Resources and Services Administration oversees the 340B program. Program details are at hrsa.gov.

What Clinicians Should Document to Maximize Approval Rates

The American Association of Clinical Endocrinology (AACE) 2023 diabetes management guidelines state: "GLP-1 receptor agonists are preferred over other non-metformin agents in patients with established atherosclerotic cardiovascular disease, multiple cardiovascular risk factors, obesity, or chronic kidney disease." The AACE guidelines are available at endocrine.org. Including this language in a prescriber letter, alongside the patient's specific cardiovascular risk documentation, gives the Amerigroup medical reviewer the clinical context needed to approve the request.

A prescriber writing a PA letter should include all of the following concrete data points:

• Most recent HbA1c value and date
• Most recent eGFR and date (relevant for metformin contraindication if applicable)
• Documented atherosclerotic cardiovascular disease, heart failure, or CKD diagnosis with ICD-10 codes
• Duration and outcome of prior metformin therapy
• List of all current diabetes medications with start dates
• Specific guideline citation supporting GLP-1 use in this patient's risk category

Short, numbered letters with lab values embedded perform better in PA review than long narrative letters, because the reviewing clinician can quickly confirm each criterion is met.

How the Affordable Care Act and Medicaid Expansion Affect Access

States that expanded Medicaid under the Affordable Care Act cover a larger share of low-income adults with type 2 diabetes, which directly affects how many people need to manage Amerigroup formularies for drugs like Victoza. A 2021 study in Health Affairs (N=approximately 4 million Medicaid enrollees) found that Medicaid expansion was associated with improved glycemic control and increased access to diabetes medications in expansion states versus non-expansion states. The Health Affairs study is indexed at pubmed.ncbi.nlm.nih.gov.

States that have not expanded Medicaid still operate Amerigroup programs in some cases, but the eligibility thresholds are narrower, meaning fewer working-age adults with diabetes qualify for Medicaid at all. Those patients may need to rely entirely on marketplace plans or patient assistance programs.

Dual-Eligible Members: Medicare and Medicaid Together

Patients enrolled in both Medicare and Medicaid (dual-eligibles) who are in an Amerigroup Dual-Eligible Special Needs Plan (DSNP) have their drug coverage handled through Medicare Part D, not Medicaid. This matters because Part D rules prohibit excluding drugs from coverage solely because they are expensive, as long as the drug is used for a covered indication. Victoza for type 2 diabetes is a covered Part D drug. Dual-eligible members typically pay $0 to $4.15 per prescription (the 2025 low-income subsidy cost-sharing amount for Tier 2 or Tier 3 drugs), but the exact amount depends on whether Victoza is on the plan's formulary tier and whether a tier exception has been granted.

CMS publishes the Low Income Subsidy (LIS) cost-sharing amounts annually. Current LIS information is at cms.gov.